THANK YOU FOR SUBSCRIBING
Biosight Bags $19M to Support Clinical Stage Oncology Programs
Biosight has raised $19 million to address the unmet needs in the treatment of patients who are medically weak to receive intensive chemotherapy.
FREMONT, CA: A developer of treatments for hematological malignancies and disorders, Biosight Ltd, has secured $19M in Series C financing. Israel Biotech Fund (IBF) led this round of funding along with Arkin Bio Ventures, SBI JI Innovation Fund, and additional new and existing investors. The funds bagged will be used to advance the clinical development of its lead asset BST-236 (aspacytarabine). The private clinical-stage biotech company develops innovative therapeutics for hematological malignancies and disorders, including acute myeloid leukemia and myelodysplastic syndrome.
The BST-236 is an innovative proprietary anti-metabolite that is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine. The anti-metabolite is designed to facilitate high-dose therapy with lower systemic exposure to free cytarabine and relative sparing of normal tissues. BST-236 will serve as a superior therapy for acute myeloid leukemia and other hematological malignancies and disorders, comprising older adults unfit for intensive therapy. BST-236 was granted Orphan Drug Designation from the FDA, entitling Biosight to seven years of market exclusivity upon BST-236 marketing approval for the treatment of acute myeloid leukemia. Biosight is thrilled to have received the financing as it is a testament to the potential of BST-236, a necessary new therapy to cancer patients with limited therapeutic options.
Biosight is a private clinical-stage biotech organization, developing innovative therapeutics for hematological malignancies and disorders. The company thrives on developing advanced therapeutics to enable safer and more efficient treatment for life-threatening diseases, to enhance the outcome and quality of life for patients with cancer and related diseases. Biosight is committed to provide hope and cure to cancer patients around the world.
See Also: Top Healthcare Technology Solution Companies